Needham & Company LLC Estimates RYTM FY2027 Earnings

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) - Equities researchers at Needham & Company LLC raised their FY2027 earnings per share (EPS) estimates for Rhythm Pharmaceuticals in a note issued to investors on Monday, April 14th. Needham & Company LLC analyst J. Stringer now anticipates that the company will earn $1.43 per share for the year, up from their previous estimate of $1.42. Needham & Company LLC has a "Buy" rating and a $66.00 price objective on the stock. The consensus estimate for Rhythm Pharmaceuticals' current full-year earnings is ($4.32) per share.

Other research analysts have also issued research reports about the company. Jefferies Financial Group started coverage on Rhythm Pharmaceuticals in a report on Thursday, January 2nd. They issued a "buy" rating and a $80.00 target price on the stock. Wells Fargo & Company lifted their price objective on shares of Rhythm Pharmaceuticals from $80.00 to $91.00 and gave the stock an "overweight" rating in a report on Monday, April 7th. HC Wainwright reiterated a "buy" rating and issued a $80.00 target price (up previously from $70.00) on shares of Rhythm Pharmaceuticals in a research note on Tuesday, April 8th. JMP Securities reissued a "market outperform" rating and set a $75.00 price target on shares of Rhythm Pharmaceuticals in a research report on Monday, December 23rd. Finally, Morgan Stanley reaffirmed an "overweight" rating and issued a $72.00 price objective on shares of Rhythm Pharmaceuticals in a research report on Friday, March 7th. Thirteen research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $74.92.

Rhythm Pharmaceuticals Trading Up 0.7 %

Shares of RYTM traded up $0.40 on Wednesday, reaching $61.74. The company's stock had a trading volume of 628,803 shares, compared to its average volume of 542,891. The stock has a market capitalization of $3.90 billion, a PE ratio of -14.26 and a beta of 2.32. Rhythm Pharmaceuticals has a twelve month low of $35.17 and a twelve month high of $68.58. The firm has a fifty day moving average of $54.70 and a 200-day moving average of $55.58.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.03). Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%. The business had revenue of $41.83 million for the quarter, compared to the consensus estimate of $38.48 million.

Insider Buying and Selling

In other news, EVP Yann Mazabraud sold 17,750 shares of the company's stock in a transaction dated Tuesday, April 8th. The stock was sold at an average price of $60.99, for a total value of $1,082,572.50. Following the completion of the transaction, the executive vice president now owns 22,620 shares of the company's stock, valued at $1,379,593.80. This represents a 43.97 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Joseph Shulman sold 1,281 shares of Rhythm Pharmaceuticals stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $59.43, for a total value of $76,129.83. Following the sale, the insider now directly owns 2,657 shares in the company, valued at $157,905.51. This trade represents a 32.53 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 146,641 shares of company stock valued at $8,112,177. 5.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in RYTM. SRS Capital Advisors Inc. boosted its stake in Rhythm Pharmaceuticals by 740.7% during the fourth quarter. SRS Capital Advisors Inc. now owns 454 shares of the company's stock valued at $25,000 after buying an additional 400 shares during the last quarter. Raleigh Capital Management Inc. bought a new position in shares of Rhythm Pharmaceuticals during the 4th quarter valued at approximately $28,000. SBI Securities Co. Ltd. purchased a new position in shares of Rhythm Pharmaceuticals in the fourth quarter valued at $37,000. R Squared Ltd bought a new stake in Rhythm Pharmaceuticals in the fourth quarter worth $44,000. Finally, State of Wyoming purchased a new stake in Rhythm Pharmaceuticals during the fourth quarter valued at $61,000.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.